Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Isoflurane

Isoflurane

Isoflurane is a volatile anesthetic agent commonly used in medical and veterinary settings.
It is a halogenated ether that produces rapid, dose-dependent anesthesia with minimal cardiovascular depression.
Isoflurane has a low blood/gas solubility coefficient, allowing for quick induction and recovery times.
It is frequently used for general anesthesia during surgical procedures, as well as for sedation and pain management.
Researchers can optimize their Isoflurane research process with PubCompare.ai, an AI-driven platform that helps locate relevant protocols from literature, preprints, and patents, while providing detailed comparisons to identify the most accurate and reproducible methods.
This can enhance research accuracy and reproducibility.
PubCompare.ai is a valuable tool for researchers working with Isoflurane to improve their study outcomes.

Most cited protocols related to «Isoflurane»

1
Comparative Assessment of Mechanosensory Thresholds
Cited 111 times
All prospective mechanosensitivity experiments with animals were conducted in accordance with the guidelines from the Canadian Council on Animal Care and approval of the Laval University Animal Care Committee. PWT was measured in adult male C57BL/6 mice using von Frey filaments 2 through 9. Mice were placed in acrylic chambers (5.5 × 10 cm) suspended above a wire mesh grid and allowed to acclimatize to the testing apparatus for 1 hour prior to experiments. When the mouse was not moving the von Frey filaments were pressed against the plantar surface of the paw until the filament buckled and held for a maximum of 3 seconds. A positive response was noted if the paw was sharply withdrawn on application of the filament. Flinching immediately upon removal of the filament was also considered a positive response as previously described [3 (link)]. Testing began with filament number 5 and progressed according to an up-down method. Mice were randomly assigned to be tested either with the method of Chaplan et al. [3 (link)] or SUDO. After the first measurement of PWT, a second measurement of PWT was conducted using the alternate test. In some prospective experiments, hyperalgesia was induced by intraplantar injection of capsaicin (0.5% w/v, 5 μl) or complete Freund’s adjuvant (CFA; 10 μl) in one hind paw under brief anesthesia with isoflurane (<3 minutes, 4% isoflurane). PWT was measured 3 hours after intraplantar injection of either compound and again 3 days after injection of CFA. The PWT estimates derived using SUDO or the method of Chaplan et al. [3 (link)] for each condition were compared using a paired t-test in Graphpad Prism 5.
Bonin R.P., Bories C, & De Koninck Y. (2014). A simplified up-down method (SUDO) for measuring mechanical nociception in rodents using von Frey filaments. Molecular Pain, 10, 26.
Full text: Click here
Publication 2014
Adult Anesthesia Animal Care Committees Animals ARID1A protein, human Capsaicin Cytoskeletal Filaments Freund's Adjuvant Hyperalgesia Isoflurane Males Mice, House Mice, Inbred C57BL prisma
2
Cranial Window Implantation for Chronic Imaging in Mice
Cited 107 times
After 2-4 weeks of expression, mice were anesthetized using isoflurane (3% for induction, 1.5-2% during surgery) and a circular craniotomy (2-3 mm diameter) was made above V1 (centered 2.7 mm lateral from the lambda suture). For acute experiments, the craniotomy was covered with agarose (1-1.3 %), and a round glass coverslip (Warner Instruments; 5mm diameter; #1 thickness) was cemented to the skull to reduce motion of the exposed brain. A custom titanium head post was fixed to the skull using black dental cement (Contemporary Ortho-Jet). For simultaneous imaging and cell-attached recording, the exposed brain was covered with ∼1 mm thick agarose (1.3%) without a coverslip. For chronic imaging experiments, the imaging window was constructed from two layers of microscope coverglass6 (link). A larger piece (Fisher, #1 thickness) was attached to the bone and a smaller insert (#2 thickness) was fitted snugly into the craniotomy. Imaging experiments were started ∼1-2 weeks after chronic window implantation.
Chen T.W., Wardill T.J., Sun Y., Pulver S.R., Renninger S.L., Baohan A., Schreiter E.R., Kerr R.A., Orger M.B., Jayaraman V., Looger L.L., Svoboda K, & Kim D.S. (2013). Ultra-sensitive fluorescent proteins for imaging neuronal activity. Nature, 499(7458), 295-300.
Publication 2013
Bones Brain Cells Craniotomy Cranium Dental Cements Head Isoflurane Microscopy Mus Operative Surgical Procedures Ovum Implantation Sepharose Sutures Titanium
3
In Vivo Two-Photon Imaging of Mouse Brain
Cited 87 times
Mice were placed on a warm blanket (37°C) and kept anesthetized with 0.5% isoflurane and sedated with chlorprothixene (20-40 μL at 0.33 mg/ml, i.m.)30 (link). Imaging was performed using a custom-built two-photon microscope (designs available at research.janelia.org/Svoboda) equipped with a resonant galvo scanning module (Thorlabs), controlled by ScanImage (scanimage.org)60 (link). The light source was a Mai Tai femtosecond pulsed laser (Spectra-Physics) running at 940 nm. The objective was a 16× water immersion lens (Nikon, 0.8 NA, 3 mm working distance). The power used was 35-50 mW for full field imaging (Fig. 2) and 20-40 mW for higher zoom imaging (Fig. 3-6).
Images were collected at 15 Hz (512 × 512 pixels, 250 μm × 250 μm; Fig. 2) or 60 Hz (256 × 256 pixels, 30 μm × 30 μm; Fig. 3), or 15 Hz (512 × 512 pixels, 30 μm × 30 μm; Fig. 4-5), or 15 Hz (512 × 512 pixels, 30 μm × 30 μm - 100 μm × 100 μm; Fig. 6). For dendritic imaging experiments (Fig. 4-6), fields of view were chosen so that extended dendritic segments were in one focal plane. At the end of each imaging session, z-stacks (1 μm step size) of the recorded cells were acquired. The coordinates of the imaged dendrites relative to the parent somata were recorded. The orientation, curvature, and the branching pattern of the dendrites together with the constellation of spines, helped to precisely identify the same field of view in long-term imaging experiments.
Chen T.W., Wardill T.J., Sun Y., Pulver S.R., Renninger S.L., Baohan A., Schreiter E.R., Kerr R.A., Orger M.B., Jayaraman V., Looger L.L., Svoboda K, & Kim D.S. (2013). Ultra-sensitive fluorescent proteins for imaging neuronal activity. Nature, 499(7458), 295-300.
Publication 2013
Carisoprodol Cells Chlorprothixene Dendrites Isoflurane Lens, Crystalline Light Microscopy Mus Submersion Vertebral Column
4
Gliosis and Behavioral Consequences
Cited 41 times
All procedures followed the Institute of Laboratory Animal Research guidelines and were approved by the Animal Care and Use Committee of the National Institute of Mental Health. Transgenic mice expressing HSV-TK under the GFAP promoter were generated from a previously-generated plasmid28 (link) using standard techniques and bred on a mixed C57Bl/6:CD-1 background. Male v-WT and v-TK mice were treated with valganciclovir for 8 weeks (dexamethasone experiment), 10-19 weeks (endocrine), 12 weeks (behavior) or 4 weeks (histology; histology after 12 weeks in Supplementary Fig. 1), beginning at 8 weeks of age. Male C57Bl/6 mice were irradiated under pentobarbital anesthesia, as described previously29 (link), and tested 9 weeks later. For immunohistochemical analyses, mice were given BrdU 6 weeks (for PVN analysis) or 24 hours prior to sacrifice, brain sections were immunostained as previously described29 (link), and labeled cells were counted stereologically.
Serum corticosterone was measured by radioimmunoassay (MP Biomedicals) from submandibular blood samples obtained directly from the home cage condition or after exploration of a novel box, restraint, or isoflurane exposure. For the dexamethasone suppression test, dexamethasone (Sigma; 50 μg/kg in propylene glycol) or vehicle were injected 90 min prior to restraint, and blood was sampled immediately following 10 min restraint.
Behavioral tests were performed following 30 min of restraint or directly from the home cage. Different cohorts of mice were tested in the NSF test, elevated plus maze, forced swim test and sucrose preference test as previously described.12 (link), 18 (link), 21 , 30 (link) Statistical analyses were performed by t-test, log-rank test, or ANOVA with Fisher's LSD test for post hoc comparisons. Significance was set at P<0.05.
Snyder J.S., Soumier A., Brewer M., Pickel J, & Cameron H.A. (2011). Adult hippocampal neurogenesis buffers stress responses and depressive behavior. Nature, 476(7361), 458-461.
Publication 2011
Anesthesia Animals Animals, Laboratory Behavior Test BLOOD Brain Bromodeoxyuridine Cells Corticosterone Dexamethasone Elevated Plus Maze Test Glial Fibrillary Acidic Protein Isoflurane Males Mice, Inbred C57BL Mice, Laboratory Mice, Transgenic neuro-oncological ventral antigen 2, human Pentobarbital Propylene Glycol Radioimmunoassay Serum Sucrose System, Endocrine Valganciclovir
5
Murine Ischemia-Reperfusion Injury Protocol
Cited 38 times
This I/R injury procedure in mice is essentially the same as the procedure for inducing MI except that a slipknot is tied around the LCA 2-3 mm from its origin with a 6-0 silk suture as shown in Fig. 2A. The heart is then quickly placed back into the thoracic space followed by manual evacuation of air and the skin closing (Fig. 2B). The internal needle end of slipknot suture is cut as short as possible and the other end of the suture is approximately 0.8 cm long and remains outside of the chest (Fig. 2C). After 30 min of ischemia, the slipknot is released by pulling the long end of slipknot suture smoothly and gently until a feeling of release is sensed at which time the myocardium begins reperfusing. This outside-the-skin suture knot releasing method should only be attempted by the experienced surgeon. Alternatively, the mouse can be re-anesthetized with 2% isoflurane inhalation, the chest reopened, and the slipknot released by pulling the long end of slipknot suture smoothly and gently, and then following manual evacuation of the pneumothorax and chest closure. As above for the MI model, ventilation is recommended until times are fast enough to do this procedure without ventilation.
Gao E., Lei Y.H., Shang X., Huang Z.M., Zuo L., Boucher M., Fan Q., Chuprun J.K., Ma X.L, & Koch W.J. (2010). A Novel and Efficient Model of Coronary Artery Ligation and Myocardial Infarction in the Mouse. Circulation research, 107(12), 1445-1453.
Publication 2010
Chest Heart Inhalation Injuries Ischemia Isoflurane Mice, Laboratory Myocardium Needles Pneumothorax Silk Skin Surgeons Sutures

Most recents protocols related to «Isoflurane»

1
Optimizing Antibody Expression and Pharmacokinetics
Not available on PMC !

Example 1

The sequence coding for the light chain variable region of the antibody was inserted into vector pFUSE2ss-CLIg-hK (Invivogen, Catalog Number: pfuse2ss-hclk) using EcoRI and BsiWI restriction sites to construct a light chain expression vector. The sequence coding for the heavy chain variable region of the antibody was inserted into vector pFUSEss-CHIg-hG2 (Invivogen, Catalog Number: pfusess-hchg2) or vector pFUSEss-CHIg-hG4 (Invivogen, Catalog Number: pfusess-hchg4) using EcoRI and NheI restriction sites to construct a heavy chain expression vector.

The culture and transfection of Expi293 cells were performed in accordance with the handbook of Expi293™ Expression System Kit from Invitrogen (Catalog Number: A14635). The density of the cells was adjusted to 2×106 cells/ml for transfection, and 0.6 μg of the light chain expression vector as described above and 0.4 μg of the heavy chain expression vector as described above were added to each ml of cell culture, and the supernatant of the culture was collected four days later.

The culture supernatant was subjected to non-reduced SDS-PAGE gel electrophoresis in accordance with the protocol described in Appendix 8, the Third edition of the “Molecular Cloning: A Laboratory Manual”.

Pictures were taken with a gel scanning imaging system from BEIJING JUNYI Electrophoresis Co., LTD and in-gel quantification was performed using Gel-PRO ANALYZER software to determine the expression levels of the antibodies after transient transfection. Results were expressed relative to the expression level of control antibody 1 (control antibody 1 was constructed according to U.S. Pat. No. 7,186,809, which comprises a light chain variable region as set forth in SEQ ID NO: 10 of U.S. Pat. No. 7,186,809 and a heavy chain variable region as set forth in SEQ ID NO: 12 of U.S. Pat. No. 7,186,809, the same below) (control antibody 2 was constructed according to U.S. Pat. No. 7,638,606, which comprises a light chain variable region as set forth in SEQ ID NO: 6 of U.S. Pat. No. 7,638,606 and a variable region as set forth in SEQ ID NO: 42 of U.S. Pat. No. 7,638,606, the same below). See Tables 2a-2c below for the results.

TABLE 2a
Expression levels of the antibodies of the present
invention after transient transfection (antibodies whose
expression levels are significantly higher than that of control antibody 1):
Number ofExpression level vsNumber of Expression level vs
the antibodycontrol antibody 1the antibodycontrol antibody 1
L1021H10002.08L1000H10281.27
L1020H10001.58L1000H10151.19
L1000H10271.56L1000H10321.18
L1000H10241.51L1000H10261.15
L1000H10251.48L1021H10291.12
L1001H10001.48L1000H10301.1
L1021H10161.43L1024H10311.08
L1000H10141.35L1000H10161.05

TABLE 2b
Expression levels of the antibodies of the present
invention after transient transfection (antibodies whose
expression levels are slightly lower than that of control antibody 1):
Number of Expression level vsNumber of Expression level vs
the antibodycontrol antibody 1the antibodycontrol antibody 1
L1000H10310.99L1017H10000.85
L1021H10310.99L1020H10160.84
L1020H10290.96L1000H10090.81
control anti-0.93L1000H10070.8
body 2
L1012H10000.89L1000H10230.8
L1019H10000.87L1020H10270.78
L1020H10310.87L1024H10070.77
L1021H10200.87L1000H10130.75
L1000H10290.86L1020H10070.74
L1008H10000.86L1021H10070.74
L1000H10010.85L1000H10210.71

TABLE 2c
Expression levels of the antibodies of the present
invention after transient transfection (antibodies whose
expression levels are significantly lower than that of control antibody 1):
Number ofExpression level vsNumber of Expression level vs
the antibodycontrol antibody 1the antibodycontrol antibody 1
L1000H10200.69L1024H10000.52
L1010H10000.69L1000H10080.51
L1000H10220.67L1000H10370.5
L1000H10120.64L1007H10000.49
L1022H10000.64L1016H10000.49
L1011H10000.63L1000H10170.47
L1000H10110.62L1000H10350.46
L1000H10330.62L1012H10270.46
L1020H10200.61L1018H10000.44
L1000H10360.6L1023H10000.43
L1021H10270.6L1012H10160.42
L1012H10070.59L1013H10000.41
L1009H10000.57L1000H10340.4
L1012H10200.57L1000H10180.35
L1012H10310.56L1000H10190.34
L1000H10380.54L1015H10000.27
L1012H10290.54L1014H10000.17
L1000H10100.53

Example 4

6-8 week-old SPF Balb/c mice were selected and injected subcutaneously with antibodies (the antibodies of the present invention or control antibody 2) in a dose of 5 mg/kg (weight of the mouse). Blood samples were collected at the time points before administration (0 h) and at 2, 8, 24, 48, 72, 120, 168, 216, 264, 336 h after administration. For blood sampling, the animals were anesthetized by inhaling isoflurane, blood samples were taken from the orbital venous plexus, and the sampling volume for each animal was about 0.1 ml; 336 h after administration, the animals were anesthetized by inhaling isoflurane and then euthanized after taking blood in the inferior vena cava.

No anticoagulant was added to the blood samples, and serum was isolated from each sample by centrifugation at 1500 g for 10 min at room temperature within 2 h after blood sampling. The collected supernatants were immediately transferred to new labeled centrifuge tubes and then stored at −70° C. for temporary storage. The concentrations of the antibodies in the mice were determined by ELISA:

1. Preparation of Reagents

sIL-4Rα (PEPRO TECH, Catalog Number: 200-04R) solution: sIL-4Rα was taken and 1 ml ddH2O was added therein, mixed up and down, and then a solution of 100 μg/ml was obtained. The solution was stored in a refrigerator at −20° C. after being subpacked.

Sample to be tested: 1 μl of serum collected at different time points was added to 999 μl of PBS containing 1% BSA to prepare a serum sample to be tested of 1:1000 dilution.

Standard sample: The antibody to be tested was diluted to 0.1 μg/ml with PBS containing 1% BSA and 0.1% normal animal serum (Beyotime, Catalog Number: ST023). Afterwards, 200, 400, 600, 800, 900, 950, 990 and 1000 μl of PBS containing 1% BSA and 0.1% normal animal serum were respectively added to 800, 600, 400, 200, 100, 50, 10 and 0 μl of 0.1 μg/ml antibodies to be tested, and thus standard samples of the antibodies of the present invention were prepared with a final concentration of 80, 60, 40, 20, 10, 5, 1, or 0 ng/ml respectively.

2. Detection by ELISA

250 μl of 100 μg/ml sIL-4Rα solution was added to 9.75 ml of PBS, mixed up and down, and then an antigen coating buffer of 2.5 μg/ml was obtained. The prepared antigen coating buffer was added to a 96-well ELISA plate (Corning) with a volume of 100 μl per well. The 96-well ELISA plate was incubated overnight in a refrigerator at 4° C. after being wrapped with preservative film (or covered). On the next day, the 96-well ELISA plate was taken out and the solution therein was discarded, and PBS containing 2% BSA was added thereto with a volume of 300 μl per well. The 96-well ELISA plate was incubated for 2 hours in a refrigerator at 4° C. after being wrapped with preservative film (or covered). Then the 96-well ELISA plate was taken out and the solution therein was discarded, and the plate was washed 3 times with PBST. The diluted standard antibodies and the sera to be detected were sequentially added to the corresponding wells, and three duplicate wells were made for each sample with a volume of 100 μl per well. The ELISA plate was wrapped with preservative film (or covered) and incubated for 1 h at room temperature. Subsequently, the solution in the 96-well ELISA plate was discarded and then the plate was washed with PBST for 3 times. Later, TMB solution (Solarbio, Catalog Number: PR1200) was added to the 96-well ELISA plate row by row with a volume of 100 μl per well. The 96-well ELISA plate was placed at room temperature for 5 minutes, and 2 M H2SO4 solution was added in immediately to terminate the reaction. The 96-well ELISA plate was then placed in flexstation 3 (Molecular Devices), the values of OD450 were read, the data were collected and the results were calculated with Winnonlin software. The pharmacokinetic results were shown in FIG. 1 and Table 6 below.

TABLE 6
Pharmacokinetic results of the antibodies of the present invention in mouse
Area
TimeUnder the
HalftoPeakdrug-timeVolume ofClearance
lifepeakconcentrationCurvedistributionrate
Numberhhμg/mlh*μg/mlml/kgml/h/kg
L1020H1031Mean269.347233.797679.28138.920.38
value
Standard105.730.000.42163.9122.480.09
deviation
L1012H1031Mean167.274845.59852.391.30.38
value
Standard8.520.001.86448.345.580.00
deviation
ControlMean56.67367.881132.68288.923.79
antibody 2value
Standard25.8416.970.2594.4249.451.12
deviation

Example 5

A series of pharmacokinetic experiments were carried out in Macaca fascicularises to further screen antibodies.

3-5 year-old Macaca fascicularises each weighting 2-5 Kg were selected and injected subcutaneously with antibodies (the antibodies of the present invention or control antibody 2) in a dose of 5 mg/kg (weight of the Macaca fascicularis). The antibody or control antibody 2 to be administered was accurately extracted with a disposable aseptic injector, and multi-point injections were made subcutaneously on the inner side of the thigh of the animal, and the injection volume per point was not more than 2 ml. Whole blood samples were collected from the subcutaneous vein of the hind limb of the animal at the time points before administration (0 h) and at 0.5, 2, 4, 8, 24, 48, 72, 120, 168, 240, 336 h, 432 h, 504 h, 600 h, 672 h after administration. The blood volume collected from each animal was about 0.1 ml each time.

No anticoagulant was added to the blood samples, and serum was isolated from each sample by centrifugation at 1500 g for 10 min at room temperature within 2 h after blood sampling. The collected supernatants were immediately transferred to new labeled centrifuge tubes and then stored at −70° C. for temporary storage. The concentrations of the antibodies in the Macaca fascicularises were determined according the method as described in Example 4. The pharmacokinetic results are shown in FIG. 2 and Table 7 below.

TABLE 7
Pharmacokinetic results of the antibodies of the present invention in macaca fascicularis
Area
TimeUnder the
HalftoPeakdrug-timeVolume ofClearance
lifepeakconcentrationCurvedistributionrate
Numberhhμg/mlh*μg/mlml/kgml/h/kg
L1020H1031Mean254.9548.0089.6522189.9175.940.22
value
Standard44.5733.9444.298557.1522.950.10
deviation
L1012H1031Mean185.75486516185.7373.410.28
value
Standard42.5433.944.52506.980.810.06
deviation
ControlMean37.031637.822773.2193.971.78
antibody 2value
Standard18.0311.316.75155.8442.470.07
deviation

Example 10

In vivo pharmacokinetics of the antibodies of the invention are further detected and compared in this Example, in order to investigate the possible effects of specific amino acids at specific positions on the pharmacokinetics of the antibodies in animals. The specific experimental method was the same as that described in Example 4, and the results are shown in Table 9 below.

TABLE 9
Detection results of in vivo pharmacokinetics of the antibodies of the present invention
Area
TimeUnder the
HalftoPeakdrug-timeVolume ofClearance
lifepeakconcentrationCurvedistributionrate
hhug/mlh*ug/mlml/kgml/h/kg
L1020H1031Mean185.494038.948188.8114.280.43
value
Standard18.5213.862.33510.476.50.05
deviation
L1012H1001Mean161.2648.0012.362491.19332.791.47
value
Standard54.300.002.26165.1676.910.20
deviation
L1001H1031Mean171.4156.0042.749273.7399.170.40
value
Standard6.1213.867.381868.6618.690.07
deviation
L1020H1001Mean89.0064.0020.113481.40164.141.30
value
Standard16.7013.862.14268.3922.860.20
deviation

From the specific sequence, the amino acid at position 103 in the sequence of the heavy chain H1031 (SEQ ID NO. 91) of the antibody (in CDR3) is Asp (103Asp), and the amino acid at position 104 is Tyr (104Tyr). Compared with antibodies that have no 103Asp and 104Tyr in heavy chain, the present antibodies which have 103Asp and 104Tyr have a 2- to 4-fold higher area under the drug-time curve and an about 70% reduced clearance rate.

The expression levels of the antibodies of the present invention are also detected and compared, in order to investigate the possible effects of specific amino acids at specific positions on the expression of the antibodies. Culture and transfection of Expi293 cells were conducted according to Example 1, and the collected culture supernatant was then passed through a 0.22 μm filter and then purified by GE MabSelect Sure (Catalog Number: 11003494) Protein A affinity chromatography column in the purification system GE AKTA purifier 10. The purified antibody was collected and concentrated using Amicon ultrafiltration concentrating tube (Catalog Number: UFC903096) and then quantified. The quantitative results are shown in Table 10 below.

TABLE 10
Detection results of the expression
levels of the antibodies of the present invention
Expression level
Antibody(×10−2 mg/ml culture medium)
L1020H10318.39
L1001H10311.79
L1020H10014.04
L1012H10015.00
L1023H10014.63
L1001H10011.75

From the specific sequence, the amino acid at position 31 in the sequence of the light chain L1012 (SEQ ID NO. 44), L1020 (SEQ ID NO. 55) or L1023 (SEQ ID NO. 51) of the antibody (in CDR1) is Ser (31Ser). Compared with antibodies that have no 31Ser in light chain, the present antibodies which have 31Ser have a 2- to 5-fold higher expression level.

The above description for the embodiments of the present invention is not intended to limit the present invention, and those skilled in the art can make various changes and variations according to the present invention, which are within the protection scope of the claims of the present invention without departing from the spirit of the same.

US11866491B2. Antibody for binding to interleukin 4 receptor (2024-01-09). SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. [CN]. Inventors: Wei Zheng [US], Wubin Pan [CA], Xin Yang [CN], Yang Chen [CN], Limin Zhang [CN], Jie Jiang [CN].
Full text: Click here
Patent 2024
Amino Acids Animals Antibodies Anticoagulants Antigens Asepsis BLOOD Blood Volume Buffers Cell Culture Techniques Cells Centrifugation Chromatography Chromatography, Affinity Cloning Vectors Culture Media Deoxyribonuclease EcoRI Drug Kinetics Electrophoresis Enzyme-Linked Immunosorbent Assay Hindlimb Human Body Immunoglobulin Heavy Chains Immunoglobulin Light Chains Immunoglobulins Interleukin-1 Isoflurane Light Macaca Macaca fascicularis Medical Devices Metabolic Clearance Rate Mice, Inbred BALB C Mus Open Reading Frames Pharmaceutical Preparations Pharmaceutical Preservatives SDS-PAGE Serum Staphylococcal Protein A Technique, Dilution Thigh Transfection Transients Ultrafiltration Veins Vena Cavas, Inferior
2
Hindlimb Suspension in Aging Rats
All procedures were approved by the University of Kentucky’s Institutional Animal Care and Use Committee. Male Brown Norway/F344 rats at 10 months of age (National Institute on Aging, Bethesda, MD) were used in this study. Rats were randomly assigned into one of four groups: weight-bearing control conditions (WB), hindlimb suspension (HS) for 4 h (4h HS), HS for 24 h (24h HS), and HS for 7 days (7d HS). Rats were allowed free access to food and water at all times and were housed on a 12:12-h light-dark cycle. Hindlimb suspension was performed as previously described [22 (link)]. Briefly, a tail device containing a hook was attached with gauze and cyanoacrylate glue while the animals were anesthetized with isoflurane (2% by inhalation). The tail device was connected via a thin cable to a pulley sliding on a vertically adjustable stainless steel bar running longitudinally above a high-sided cage. The system was designed in such a way that the rats could not rest their hindlimbs against any side of the cage but could move around the cage on their front limbs and could reach water and food easily. Cages were randomly placed in the room, and the room temperature was 27 °C.
Ismaeel A., Van Pelt D.W., Hettinger Z.R., Fu X., Richards C.I., Butterfield T.A., Petrocelli J.J., Vechetti I.J., Confides A.L., Drummond M.J, & Dupont-Versteegden E.E. (2023). Extracellular vesicle distribution and localization in skeletal muscle at rest and following disuse atrophy. Skeletal Muscle, 13, 6.
Full text: Click here
Publication 2023
Animals Cyanoacrylates Food Forehead Hindlimb Inhalation Institutional Animal Care and Use Committees Isoflurane Males Medical Devices Rats, Inbred BN Rats, Inbred F344 Rattus norvegicus Stainless Steel Tail
3
Immunofluorescence Staining of Brain Tissue
Immunofluorescence staining was performed as previously described with modifications [45 (link), 46 (link)]. Mice were euthanized by isoflurane overdose at each time point. The brains were sectioned at 20 µM of thickness, fixed with 4% paraformaldehyde (Thermo Fisher) for 15 min, then permeabilized with 0.1% Triton X-100 for 10 min. After washing with the phosphate-buffered saline (PBS) for 15 min, the sections were blocked for 1 h and incubated overnight with primary antibodies for ZO-1 (1:100, Thermo Fisher) claudin-5 (1: 100, Thermo Fisher) and GFAP (1:100, Cell Signaling), respectively. Alexa fluorescent secondary antibodies (Thermo Fisher) were used at 1:400 dilutions for 1 h. After counterstaining with 4′,6-diamidino-2-phenylindole (DAPI) for nucleus and washing with PBS, the sections were mounted with Permount (Thermo Fisher). The whole sections were scanned with a Leica Stellaris SP8 Falcon microscope (Leica Microsystem) and the images (20X magnitude) were captured with the same microscope. Mean total fluorescence intensity was calculated for each color channel and intensity of green color (ZO-1/GFAP) and red color (claudin-5) was expressed relative to blue color (DAPI). Cortex and hippocampus of both hemispheres of each brain section were used to evaluate the expression levels of ZO-1, claudin-5 and GFAP. To minimize the subjective bias, all images for ZO-1, claudin-5 and GFAP expression analysis were captured under the same microscopic parameter (laser power, pinhole size, exposure time) setting.
Archie S.R., Sifat A.E., Zhang Y., Villalba H., Sharma S., Nozohouri S, & Abbruscato T.J. (2023). Maternal e-cigarette use can disrupt postnatal blood-brain barrier (BBB) integrity and deteriorates motor, learning and memory function: influence of sex and age. Fluids and Barriers of the CNS, 20, 17.
Full text: Click here
Publication 2023
Antibodies Brain Cell Nucleus Cerebral Hemispheres Claudin-5 Cortex, Cerebral Drug Overdose Fluorescence Fluorescent Antibody Technique Glial Fibrillary Acidic Protein Isoflurane Microscopy MLL protein, human Mus paraform Phosphates Saline Solution Seahorses Technique, Dilution Triton X-100
4
Neuroimaging of Anesthetized Ferrets

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Agar Anesthesia Anesthetics Animals Bone Screws Brain Cerebrospinal Fluid Cortex, Cerebral Craniotomy Cranium Dehydration Dura Mater Eye Movements Ferrets Glucose Isoflurane Ketamine Lactated Ringer's Solution Operative Surgical Procedures Oxide, Nitrous Oxygen Pentobarbital Sodium physiology Punctures Rate, Heart Reading Frames Respiratory Rate Rocuronium Bromide Saline Solution Saturation of Peripheral Oxygen Scalp Temporal Muscle Tissues Trachea Tracheostomy Visual Cortex Xylazine
5
Assessing Lung Injury and Inflammation in Mice

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Albumins Anesthesia Animals Cytokine Diet Eosin Eucalyptus Food Histones Inhalation Injections, Intraperitoneal Injuries Institutional Animal Care and Use Committees Isoflurane Ketamine Lung Lung Injury Males Mice, Inbred C57BL Mus Obstetric Delivery Oropharynxs physiology Rivers Rodent Saline Solution Smoke Tissue Harvesting Xylazine

Top products related to «Isoflurane»

1
Vevo 2100 by Fujifilm
Sourced in Canada, United States, Japan
The Vevo 2100 is a high-resolution, real-time in vivo imaging system designed for preclinical research. It utilizes advanced ultrasound technology to capture detailed images and data of small animal subjects.
2
Isoflurane by Baxter
Sourced in United States, Germany, Sweden, France, Denmark, United Kingdom, Canada, Italy, Norway, Austria, Switzerland, Poland, Puerto Rico, Belgium, Australia, Spain, Finland
Isoflurane is a volatile anesthetic agent used in the medical field. It is a clear, colorless, and nonflammable liquid that is vaporized and administered through inhalation. Isoflurane is primarily used to induce and maintain general anesthesia during surgical procedures.
3
Isoflurane by Abbott
Sourced in United States, United Kingdom, Germany, Japan, Switzerland, Canada, Israel, Sweden, China, France, Brazil, Australia, Cameroon, Spain, Belgium
Isoflurane is an inhaled anesthetic agent used to induce and maintain general anesthesia in medical and veterinary settings. It is a clear, colorless, and volatile liquid. Isoflurane functions as a potent and effective anesthetic by depressing the central nervous system, resulting in unconsciousness, analgesia, and muscle relaxation.
4
Living image software by PerkinElmer
Sourced in United States, United Kingdom, France, Switzerland, China
Living Image software is a data acquisition and analysis platform designed for in vivo optical imaging. It enables the collection and processing of bioluminescence and fluorescence imaging data from preclinical imaging systems.
5
Vt1200 by Leica
Sourced in Germany, United States, United Kingdom, Japan, Australia, Canada, Israel, Switzerland
The VT1200S is a vibrating microtome designed for precision sectioning of biological samples. It features a high-precision feed system and a stable base for consistent, uniform sectioning.
6
Vevo 770 by Fujifilm
Sourced in Canada, United States, Japan
The Vevo 770 is a high-resolution, real-time, in vivo micro-imaging system designed for small animal research. It employs high-frequency ultrasound technology to produce detailed anatomical and functional images.
7
C57bl 6j mice by Jackson ImmunoResearch
Sourced in United States, Montenegro, Japan, Canada, United Kingdom, Germany, Macao, Switzerland, China
C57BL/6J mice are a widely used inbred mouse strain. They are a commonly used model organism in biomedical research.
8
Ivis spectrum by PerkinElmer
Sourced in United States, Germany, France, China
The IVIS Spectrum is a bioluminescence and fluorescence imaging system designed for preclinical research. It enables non-invasive, real-time visualization and quantification of biological processes in living small animal models.
9
Stereotaxic frame by Kopf Instruments
Sourced in United States, Germany, Italy
The Stereotaxic frame is a laboratory instrument used to immobilize and position the head of a subject, typically an animal, during surgical or experimental procedures. It provides a secure and reproducible method for aligning the subject's head in a three-dimensional coordinate system to enable precise targeting of specific brain regions.
10
Vevo 2100 imaging system by Fujifilm
Sourced in Canada, United States
The Vevo 2100 Imaging System is a high-resolution ultrasound platform designed for preclinical research applications. It provides real-time, high-quality imaging of small animals and other biological samples.

More about "Isoflurane"

Isoflurane is a widely used volatile anesthetic agent in both medical and veterinary settings.
This halogenated ether compound rapidly induces dose-dependent anesthesia with minimal cardiovascular impact, thanks to its low blood-gas solubility coefficient.
Isoflurane's quick induction and recovery times make it a popular choice for general anesthesia during surgical procedures, as well as for sedation and pain management applications.
Researchers working with Isoflurane can optimize their research process by utilizing PubCompare.ai, an AI-driven platform that helps locate relevant protocols from literature, preprints, and patents.
This tool provides detailed comparisons to identify the most accurate and reproducible methods, enhancing research accuracy and reproducibility.
PubCompare.ai is a valuable resource for Isoflurane researchers looking to improve their study outcomes.
For in vivo Isoflurane research, complementary technologies like the Vevo 2100 ultrasound imaging system, Living Image software, and IVIS Spectrum imaging platform can be leveraged.
Stereotaxic frames are often used in conjunction with Isoflurane anesthesia for precise surgical procedures in small animal models like C57BL/6J mice.
The VT1200S anesthesia system and Vevo 770 imaging platform are additional tools that can support high-quality Isoflurane-based research.
By utilizing these integrated solutions, researchers can optimize their Isoflurane-related workflows and enhance the accuracy, reproducibility, and overall impact of their studies.